Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2018-06-21. The firm is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The firm has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

DNTH Profile, Market Tickers and Other

DNTH profile